CD19 and diffuse large B-cell lymphoma: Despite the unprecedented efficacy of anti-CD19 CAR T cell therapy in relapsed or refractory diffuse large B cell lymphoma (DLBCL), long lasting remissions are observed in only about 40% of patients.1